Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moesinger, R. C.
Right arrow Articles by Pitt, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moesinger, R. C.
Right arrow Articles by Pitt, H. A.

Annals of Surgical Oncology, Vol 6, Issue 7 682-690, Copyright © 1999 by Society of Surgical Oncology

ARTICLES

Large cystic pancreatic neoplasms: pathology, resectability, and outcome

R. C. Moesinger, M. A. Talamini, R. H. Hruban, J. L. Cameron and H. A. Pitt
Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.

BACKGROUND: Cystic pancreatic neoplasms may be benign, premalignant, or malignant. These lesions may remain asymptomatic for long periods and can be quite large at the time of presentation. METHODS: A retrospective analysis was used to determine whether preoperative evaluation can predict pathology and determine resectability and outcome. RESULTS: Over 12 years, 145 cystic pancreatic neoplasms, of which 24 (17%) were larger than 10 cm, were managed at the Johns Hopkins Hospital. Those 24 large tumors included 9 of 73 cystadenomas (12%), 7 of 27 cystadenocarcinomas (26%), 2 of 35 adenocarcinomas producing mucin or associated with a cyst (6%), 5 of 9 Hamoudi tumors (55%), and 1 dermoid cyst. Clinical symptoms, liver function tests, and computed tomographic scans did not distinguish benign from malignant pathology. On 18 angiograms, 2 malignant and 4 benign neoplasms demonstrated encasement or occlusion; however, 3 of these 6 tumors were resectable. Twenty of 22 patients (91%) who were explored underwent resection with no hospital mortality. For the entire series, 5-year survival for those with cystadenomas, cystadenocarcinomas, and cystic adenocarcinomas was 97%, 38%, and 9%, respectively. Three-year survival for those 7 with cystadenocarcinomas larger than 10 cm was 54%, compared with 51% for those 20 with smaller cystadenocarcinomas. CONCLUSIONS: Preoperative evaluation usually does not predict pathology, resectability, or outcome. Moreover, resectability is high and morbidity is low, irrespective of size. Large cystic pancreatic tumors should be explored to determine pathology, attempt resection, and provide an opportunity for long-term survival.


This article has been cited by other articles:


Home page
 INT J SURG PATHOLHome page
L.-y. Lee, H.-L. Hsu, H.-M. Chen, and C. Hsueh
Ductal Adenocarcinoma of the Pancreas with Huge Cystic Degeneration: A Lesion to Be Distinguished from Pseudocyst and Mucinous Cystadenocarcinoma
International Journal of Surgical Pathology, July 1, 2003; 11(3): 235 - 239.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society of Surgical Oncology.